Fig. 7

Inhibition of S100A14 or glutaminase potentiates sorafenib against HCC xenografts. (A and B) Representative photographs and growth curves of Huh7 xenografts that were transfected with shS100A14 or NTC, and treated with sorafenib or vehicle. n = 6 mice. (C and D) Thin sections of excised tumors from panel A were subjected to (C) staining with hematoxylin-eosin (HE) or immunostaining for S100A14 or Ki67 or (D) staining in the TUNEL assay to identify apoptotic cells, with nuclear counterstaining using Hoechst dye. n = 6 mice. Scale bar in panel C, 100 μm; in panel D, 40 μm. (E and F) Representative photographs and growth curves of Huh7 xenografts treated with the glutaminase inhibitor CB-839, sorafenib or both. n = 6 mice. (G and H) Thin sections of excised tumors from panel E were subjected to (G) staining with hematoxylin-eosin (HE) or immunostaining for GLS or Ki67 or (H) staining in the TUNEL assay to identify apoptotic cells, with nuclear counterstaining using Hoechst dye. n = 6 mice. Scale bar in panel G, 100 μm; in panel H, 40 μm. ***p < 0.001